In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve : the S3U registry

Show full item record



Permalink

http://hdl.handle.net/10138/327219

Citation

Saia , F , Gandolfo , C , Palmerini , T , Berti , S , Doshi , S N , Laine , M , Marcelli , C , Piva , T , Ribichini , F , De Benedictis , M , Cardaioli , F , Cannata , S & Tarantini , G 2020 , ' In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve : the S3U registry ' , EuroIntervention journal , vol. 15 , no. 14 , pp. 1240-1247 . https://doi.org/10.4244/EIJ-D-19-00541

Title: In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve : the S3U registry
Author: Saia, Francesco; Gandolfo, Caterina; Palmerini, Tullio; Berti, Sergio; Doshi, Sagar N.; Laine, Mika; Marcelli, Chiara; Piva, Tommaso; Ribichini, Flavio; De Benedictis, Mauro; Cardaioli, Francesco; Cannata, Stefano; Tarantini, Giuseppe
Contributor: University of Helsinki, Kardiologian yksikkö
Date: 2020-02
Language: eng
Number of pages: 8
Belongs to series: EuroIntervention journal
ISSN: 1774-024X
URI: http://hdl.handle.net/10138/327219
Abstract: Aims: The aim of this study was to evaluate 30-day safety and efficacy outcomes of transcatheter aortic valve implantation (TAVI) performed with the SAPIEN 3 Ultra system. Methods and results: The S3U registry is a physician-led, post-approval, multicentre, observational registry of transfemoral TAVI with the SAPIEN 3 Ultra. New features include an improved sealing skirt, a 14 Fr expandable sheath and a new delivery catheter. Overall, 139 consecutive patients at nine participating centres were enrolled. Mean age was 81.4 +/- 8.3 years, average STS score 3.8 +/- 2.4%. The vast majority (97.2%) underwent TAVI with local anaesthesia (28.8%) or conscious sedation (68.3%). Balloon predilatation was performed in 30 patients (21.6%), post-dilatation in three (2.2%). In-hospital, there were no cases of death, stroke, or conversion to open heart surgery. Major vascular complications occurred in three patients (2.2%), as well as major or life-threatening bleedings in three patients (2.2%). There were two moderate (1.4%) and no moderate/severe paravalvular leaks. Median length of stay after TAVI was three days (IQR 3-5 days). At 30 days, there were no deaths, MI, or strokes, and the incidence of new permanent pacemaker implantation was 4.4%. Conclusions: This first multicentre international experience of transfemoral TAVI with the SAPIEN 3 Ultra transcatheter heart valve shows good in-hospital and 30-day clinical outcomes.
Subject: aortic stenosis
femoral
miscellaneous
TAVI
RISK PATIENTS
REPLACEMENT
IMPLANTATION
STENOSIS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
sapien_3_ultra_ ... e_in_hospital_and_30_1.pdf 597.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record